A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

November 30, 2010

Study Completion Date

November 30, 2010

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

Placebo

Matching placebo in capsules administered as a single oral dose.

DRUG

250 mg CK-2017357

250 mg CK-2017357 in capsules administered as a single oral dose.

DRUG

500 mg CK-2017357

500 mg CK-2017357 in capsules administered as a single oral dose.

Trial Locations (15)

13210

SUNY Upstate Medical Center, Syracuse

17033

Penn State, University Park

19102

Drexel University College of Medicine, Dept of Neurology, Philadelphia

21287

Johns Hopkins Hospital, Baltimore

27705

Duke University, Durham

32224

Mayo Clinic Florida, Jacksonville

40536

University of Kentucky, Lexington

63110

Washington University, St Louis

78229

The University of Texas Health Science Center at San Antonio, San Antonio

85018

Phoenix Neurological Associates, Ltd., Phoenix

93701

University Neurology Associates, Fresno

94115

California Pacific Medical Center, San Francisco

97213

Providence ALS Center, Portland

02114

Massachusetts General Hospital, Boston

05401

University of Vermont, Burlington

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Cytokinetics

INDUSTRY

NCT01089010 - A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS) | Biotech Hunter | Biotech Hunter